According to a recent LinkedIn post from Healthera, the company is promoting a new product called Healthera Orbit, described as an NHS‑approved integration with the Electronic Prescription Service. The post portrays Orbit as an “intelligent EPS automation assistant” that uses machine learning and automation to streamline prescription management for community pharmacies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights capabilities such as automatic tracking of EPS prescription status, learning each pharmacy’s workflow, and timing patient notifications to when prescriptions are actually ready. The post cites internal performance figures of 85% of prescriptions automated within 45 days, alongside qualitative benefits such as fewer counter interruptions and more staff time for patient care.
From an investor perspective, the emphasis on full NHS systems integration suggests that Healthera is positioning itself deeper within the U.K. healthcare IT infrastructure, which could strengthen switching costs and customer retention among pharmacies. If adoption of Orbit scales, incremental software revenue and embedded data capabilities could enhance the company’s recurring revenue profile and support higher long‑term margins.
The focus on machine learning‑driven workflow optimization aligns Healthera with broader digital health and automation trends that aim to relieve staffing pressures in primary care settings. Successful proof points around automation rates and operational benefits may improve Healthera’s competitive standing versus other prescription management and pharmacy workflow platforms, potentially supporting pricing power or expanded partnership opportunities within the NHS ecosystem.